HUTCHMED: all 118 studies
Page 2 of 2. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid TumorsCompletedNCT02590952Phase 1
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3
- A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownNCT02503033Phase 1
- A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCompletedNCT02415023Phase 1/2
- A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
- A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)CompletedNCT02320409Phase 1
- A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)CompletedNCT02314819Phase 3
- Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine TumorsCompletedNCT02267967Phase 1
- A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerCompletedNCT02252913Phase 1
- Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02133157Phase 1
- A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523CompletedNCT02105129Phase 1
- A Food Effect Phase I Study of the Volitinib in Healthy SubjectsCompletedNCT02017236Phase 1
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01985555Phase 1
- A Phase Ib Study of Fruquintinib in 3rd Line mCRCCompletedNCT01975077Phase 1/2
- Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy SubjectsCompletedNCT01955304Phase 1
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01773018Phase 1
- Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid TumorsCompletedNCT01645215Phase 1